Related Experiment Video

Updated: Jul 8, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.2K

Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates

Riste Kalamees1, Hiie Soeorg1, Mari-Liis Ilmoja2

  • 1Department of Microbiology, University of Tartu, Tartu, Estonia.

Antimicrobial Agents and Chemotherapy
|April 5, 2024
PubMed

Insights

Model-informed precision dosing software improved vancomycin target concentration achievement in neonates. This precision dosing approach enhanced therapeutic drug monitoring efficacy without increasing adverse events.

Area of Science:

  • Neonatal pharmacology
  • Pharmacokinetic/pharmacodynamic modeling
  • Infectious disease treatment

Background:

  • Vancomycin is crucial for treating neonatal infections.
  • Achieving target vancomycin concentrations is challenging in neonates.
  • Current dosing strategies have limitations in optimizing therapeutic outcomes.

Purpose of the Study:

  • To validate a model-informed precision dosing (MIPD) software for vancomycin in neonates.
  • To assess the impact of MIPD on achieving target vancomycin trough concentrations.
  • To evaluate the safety profile of MIPD compared to standard care.

Main Methods:

  • Prospective study involving 48 neonates (50 treatment episodes).
  • Utilized MIPD software based on population pharmacokinetic models for vancomycin dosing.
  • Dose adjustments were made every 36-48 hours.
  • Compared outcomes with a historical control group (53 neonates, 65 episodes).

Main Results:

  • The MIPD group achieved the target vancomycin trough concentration (10-15 mg/L) in 62% of episodes.
  • This represents a significant improvement from 37% in the historical control group (P = 0.01).
  • No significant difference in the incidence of side effects was observed between groups.

Conclusions:

  • Model-informed precision dosing software effectively improves vancomycin target concentration achievement in neonates.
  • MIPD offers a promising strategy for optimizing vancomycin therapy in neonatal populations.
  • The validated MIPD approach enhances therapeutic drug monitoring without compromising safety.
Keywords:
model-informed precision dosingneonatesvancomycin

More Related Videos

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

29.0K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.4K

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).